Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.04
- Piotroski Score 4.00
- Grade N/A
- Symbol (SANG)
- Company Sangoma Technologies Corporation
- Price $6.10
- Changes Percentage (-1.65%)
- Change -$0.1
- Day Low $6.06
- Day High $6.25
- Year High $6.75
Sangoma Technologies Corporation develops, manufactures, distributes, and supports voice and data connectivity components for software-based communication applications worldwide. The company offers Switchvox, a business phone system; PBXact, a phone system; Internet protocol (IP) phones; service provider and voice over Internet protocol gateways; Switchvox Cloud, a unified communications solution; SIPstation SIP Trunking, a hosted session initiation protocol trunking service; PBXact Cloud, a cloud based private branch exchange service; Asterisk and FreePBX, an open source IP PBX software; and FAXStation, a fax-over-IP solution. It also provides session border controllers; telephony and media transcoding cards; and open source communications software. The company serves small and medium sized businesses, enterprises, original equipment manufacturers, carriers, and service providers. Sangoma Technologies Corporation was founded in 1984 and is headquartered in Markham, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.92
- Trailing P/E Ratio -5.97
- Forward P/E Ratio -5.97
- P/E Growth -5.97
- Net Income $-8,659,000
Income Statement
Quarterly
Annual
Latest News of SANG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The Fabry program expects top-line data by Q2 2025, with the last patient visit in April 2025. FDA's supportive approach for rare diseases allowed an accelerated approval pathway for positive eGFR slo...
By Yahoo! Finance | 1 week ago -
'Hellbound' Director Yeon Sang-Ho Answers Your Burning Questions About Season 2
Yeon Sang-ho's Hellbound Season 2 delves deeper into the supernatural world where decrees predict death, monsters emerge, and resurrection occurs. Yeon discusses challenges, character inspirations, an...
By Forbes | 3 weeks ago -
Forbes Asia Best Under A Billion Forum: Leadership Advice From The Heads Of Eu Yan Sang, Minor International And Osim Owner V3
At the Forbes Asia Best Under A Billion Forum and Awards Dinner, seasoned leaders shared strategies on overcoming challenges. Ron Sim stresses innovation, William Heinecke emphasizes staying focused o...
By Forbes | 4 weeks ago
